

Fiona O'Sullivan, PhD¹, Ioannis Tomazos, PhD MBA², Francjan J van Spronsen, MD PhD³, Shelagh M. Szabo, MSc¹, Maanasa Venkataraman, MSc¹, Lavanya Huria, MSc¹, Neil Smith, PharmD MBA², Lachlan Molony, BSc², Kim Ingalls, MD², Kathleen Somera-Molina, PhD, MSCI², Cary O. Harding, MD⁴

¹Broadstreet HEOR, Vancouver, BC, Canada

²PTC Therapeutics Inc, South Plainfield, NJ, USA

³Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands

⁴Department of Molecular and Medical Genetics and Department of Pediatrics, Oregon Health & Science University, Portland, Oregon, USA

1. Background:

- In phenylketonuria (PKU), high phenylalanine (Phe) is associated with lower cognitive abilities.¹⁻²
 - Two meta-analyses on intelligence quotient (IQ) in PKU showed lower IQ in PKU patients.^{3,4}
 - A higher impact of PKU on health-related quality-of-life (HRQoL) has been reported among those with lower IQ scores.⁵
- Adhering to dietary management is challenging but is needed to preserve neurocognition.^{1,6-8}
- While development will be within normal limits, the exact impact of early continuous dietary management on cognition is not well known.⁹ Data on cognitive abilities of this group compared to controls are needed.


2. Objective:

- To synthesize published data on the cognitive impact of PKU measured by IQ scores, among patients receiving early dietary management.


4. Results continued:

CHILDREN

- Eleven studies reported IQ in overall populations of children (**Figure 2**).¹⁰⁻²⁰
- Mean (SD) full scale IQ scores ranged from 94.0 (18.6) to 104.0 (15).
 - Eight studies (72.7%) reported mean IQ <100.



- Three studies described subgroups by **dietary adherence** (Supplementary figure 1); children with poorer adherence showed poorer cognitive ability.^{10,12,21}
 - Mean (SD) full scale IQ scores in those "on diet" (ranging from 97.3 [10.3] to 106.5 [19.2]), were higher than among those "off diet" (ranging from 87.9 [NR] to 95.6 [15.3]).



3. Methods:

Overview

- A systematic literature review was conducted following PRISMA guidelines in March 2023, using MEDLINE, EMBASE and Northern Lights databases.
- Two researchers (MV, LH) independently reviewed all identified records against the PICOS criteria: Observational studies assessing IQ among early-diagnosed and treated PKU patients [blood Phe level >600 µmol/L at screening] in English.

Interpreting IQ scores

- IQ assessments by Wechsler Intelligence Scale (WIS) were included.
- IQ scores of 100 represent 'average intelligence'.
- 'Intellectual disability' is classified as an IQ<70.





Data synthesis


- Mean full scale IQ scores using the age-appropriate WIS, overall and by subgroups (e.g., children vs. adults), were extracted.
- We reported results by age and subgroup:
 - Overall population:** Data from studies that reported IQ measures for an overall PKU population, by age.
 - Restricted subgroups:** Data from studies that restricted to particular subgroups (e.g. patients who went on or off diet; by high/low Phe levels within age groups).
- Differences in IQ between PKU and comparison samples (siblings or healthy controls) from the same studies were explored.
- The percentage of studies where patients had mean IQ scores <100 was reported.

ADULTS

- Eight studies reported mean IQ scores in overall populations of adults (**Figure 4**); mean (SD) full scale IQ scores ranged from 90.0 (11.0) to 107.6 (18.7).^{19,25-31}
- Six studies (75%) reported mean IQ <100.




- Two studies restricted by **dietary adherence** (**Figure 5**): mean (SD) IQ scores were 81.0 (8.0, ended diet early) and 112.0 (NR; continuously on diet).^{25,32}
- Three studies assessing IQ among adults included an external comparison (**Figure 6**), and mean IQ scores ranged from 2 (unaffected siblings) to 16.3 (age and sex matched healthy controls) points higher than among PKU adults.^{25-26,30}
- The differences between PKU and control groups tended to be larger (except among continuously diet-adherent adults) in adults compared to children.



4. Results

OVERALL

Figure 1: PRISMA diagram of included studies that reported relevant IQ outcomes



5. Discussion:

- This synthesis revealed the impact of early dietary management on IQ; approximately three quarters of studies of children and adults reported mean IQ scores <100 (i.e., below 'average intelligence').
 - Data from comparison groups from the same studies help highlight the extent of the deficit: IQ scores among PKU samples were 5 to 16.3 points lower.
 - Higher mean IQ scores were reported among those who remained on diet compared to who did not.
- Smaller and more heterogenous samples resulted in larger variance around estimates within the adult samples.
- Strengths include:
 - The rigorous systematic review methodology employed and focus on observational studies, which can have longer follow-up (compared to trials), provide real-world insights into diet adherence, and include more generalizable samples.
 - Studies were restricted to those that defined PKU or blood Phe levels >600µmol/L at diagnosis, and to those on early treatment or dietary management, to reduce heterogeneity within the samples.
 - Subgroup analyses that revealed important insights into the changing effects of PKU on cognition across different age groups and dietary management approaches.
- Limitations include small sample sizes and considerable variability in reported estimates; and the lack of individual patient data. Presenting overall (mean) values may obscure trends in IQ in PKU.¹¹

6. Conclusions:

- Individual IQ scores among patients with PKU from studies included in our review were variable. However, a larger proportion of studies reported mean IQ scores <100 points. In addition, patients with poor dietary adherence showed poorer cognitive ability. Furthermore, mean IQ scores were consistently lower compared to control groups, despite all patients in this review receiving early dietary management.
- These data highlight that IQ is affected in PKU, even with early dietary management. Treatments that reduce Phe levels have an opportunity to reduce burden in PKU, brought upon by lower cognitive abilities.

7. References:

- van Spronsen FJ et al. Nat Rev Dis Primers. 2021 May 20;7(1):36.
- Ford S. Mol Genet Metab Rep. 2018 Oct 18;17:57-63.
- Moyle et al. Neuropsychol Rev. 2007 Jun;17(2):101-103.
- Roman et al. Neurosci Biobehav Rev. 2022 Dec;143:104925.
- Maassen-Abgoston et al. Orphanet J Rare Diseases. 2023 Sep 22;18(1):300.
- Gottlieb PV et al. Arch Dis Child. 2020 Mar;95(3):200-15.
- Shah Thomas D et al. Glob Pediatr Health. 2021 Dec 17;8:2333794X21106533.
- Bosch AM et al. Orphanet J Rare Dis. 2015 Jun 18;10:80.
- Alme K et al. Front Psychiatry. 2018 Sep 10;9:2691.
- Waisbren et al. Pediatrics. 1987;79(3):351-355.
- Pietz et al. European Journal of Pediatrics. 1988;147(4):361-367.
- Leuzzi et al. Neuropediatrics. 1993;24(3):302-306.
- Weglage et al. Pediatric Research. 1994;35(5):611-613.
- Riva et al. Acta Paediatr. 1996;85(1):56-61.
- Scheibenreiter et al. European Journal of Pediatrics. 1996;155 Suppl 1:S45-49.
- Schmidt et al. European Journal of Pediatrics. 1996;155 Suppl 1:S82-86.
- Leuzzi et al. Journal of inherited metabolic disease. 2004;27(2):115-125.
- Anastasioe et al. Mol Genet Metab. 2008;95(1-2):17-20.
- Mastrangelo et al. Mol Genet Metab. 2015;116(3):171-177.
- Herenger et al. Mol Genet Metab. 2019;126(3):246-249.
- Logsdon et al. Clin Pediatr (Phila). 1993;32(7):417-425.
- Barney et al. Psychol Rep. 1988;63(1):139-142.
- Huibrechts et al. Neuropsychology. 2003;17(3):369-379.
- Anderson et al. Dev Med Child Neurol. 2004;46(4):230-238.
- Ris et al. Journal of Pediatrics. 1994;124(3):388-392.
- Pietz et al. European Journal of Pediatrics. 1995;157(10):824-830.
- Feldmann et al. Mol Genet Metab. 2015;126(3):246-249.
- Brumm et al. Journal of Inherited Metabolic Disease. 2004;27(5):549-566.
- Pfaendner et al. AJNR Am J Neuroradiol. 2005;26(7):1681-1685.
- Nardocchia et al. Mol Genet Metab. 2015;115(2-3):84-90.
- Burgess et al. Orphanet J Rare Dis. 2021;16(1):35.
- Pietz et al. Dev Med Child Neurol. 1993;35(1):54-64.

8. Abbreviations:

EMBASE, Excerpta Medica Database
HRQoL, health-related quality of life
ID, intellectual disability
IQ, intelligence quotient
MEDLINE, Medical Literature Analysis and Retrieval System Online
NR, not reported
Phe, phenylalanine
PICOS, population, intervention, comparator, outcomes and study design
PKU, phenylketonuria
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SD, standard deviation
WIS, Wechsler Intelligence Scale

DISCLOSURES: This study was funded by PTC Therapeutics, Inc. **IT, NS, LM, KI,** and **KSM** are employees of PTC Therapeutics and may own stocks in the company. **SMS, MV, LH** and **FOS** are employees of Broadstreet HEOR, which received funds from PTC to conduct this study. **CH** and **FVS** received consulting fees related to this work. Medical writing support was provided by Broadstreet HEOR, and was funded by PTC Therapeutics.

CONTACT INFORMATION: ytomazos@ptcbio.com

